Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
8.68
+0.79 (10.01%)
At close: Mar 9, 2026, 4:00 PM EDT
8.66
-0.02 (-0.23%)
After-hours: Mar 9, 2026, 7:59 PM EDT
Vanda Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 216.11 | 198.77 | 192.64 | 254.38 | 268.68 | Upgrade
|
| Revenue Growth (YoY) | 8.72% | 3.18% | -24.27% | -5.32% | 8.27% | Upgrade
|
| Cost of Revenue | 13.04 | 11.31 | 14.8 | 24.28 | 25.63 | Upgrade
|
| Gross Profit | 203.06 | 187.46 | 177.84 | 230.1 | 243.05 | Upgrade
|
| Selling, General & Admin | 237.95 | 146.41 | 112.88 | 136.49 | 124.05 | Upgrade
|
| Research & Development | 109.27 | 74.43 | 76.82 | 85.77 | 75.36 | Upgrade
|
| Amortization of Goodwill & Intangibles | 7.01 | 7.27 | 2.09 | 1.52 | 1.48 | Upgrade
|
| Operating Expenses | 354.23 | 228.12 | 191.8 | 223.77 | 200.89 | Upgrade
|
| Operating Income | -151.17 | -40.66 | -13.95 | 6.33 | 42.17 | Upgrade
|
| Interest & Investment Income | 10.47 | 10.75 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 11.49 | 2.01 | 1.85 | Upgrade
|
| EBT Excluding Unusual Items | -140.7 | -29.92 | -2.46 | 8.34 | 44.01 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.05 | 6.99 | 8.8 | 2.96 | -1.65 | Upgrade
|
| Pretax Income | -138.65 | -22.92 | 6.34 | 11.3 | 42.36 | Upgrade
|
| Income Tax Expense | 81.83 | -4.02 | 3.83 | 5.03 | 9.21 | Upgrade
|
| Net Income | -220.47 | -18.9 | 2.51 | 6.28 | 33.15 | Upgrade
|
| Net Income to Common | -220.47 | -18.9 | 2.51 | 6.28 | 33.15 | Upgrade
|
| Net Income Growth | - | - | -60.02% | -81.07% | 42.06% | Upgrade
|
| Shares Outstanding (Basic) | 59 | 58 | 57 | 56 | 56 | Upgrade
|
| Shares Outstanding (Diluted) | 59 | 58 | 58 | 57 | 57 | Upgrade
|
| Shares Change (YoY) | 1.34% | 1.03% | 1.01% | 0.11% | 3.14% | Upgrade
|
| EPS (Basic) | -3.74 | -0.33 | 0.04 | 0.11 | 0.60 | Upgrade
|
| EPS (Diluted) | -3.74 | -0.33 | 0.04 | 0.11 | 0.58 | Upgrade
|
| EPS Growth | - | - | -63.64% | -81.03% | 38.09% | Upgrade
|
| Free Cash Flow | -110.44 | -20.48 | -88.25 | 31.31 | 63.66 | Upgrade
|
| Free Cash Flow Per Share | -1.87 | -0.35 | -1.53 | 0.55 | 1.12 | Upgrade
|
| Gross Margin | 93.96% | 94.31% | 92.32% | 90.45% | 90.46% | Upgrade
|
| Operating Margin | -69.95% | -20.46% | -7.24% | 2.49% | 15.69% | Upgrade
|
| Profit Margin | -102.02% | -9.51% | 1.30% | 2.47% | 12.34% | Upgrade
|
| Free Cash Flow Margin | -51.11% | -10.30% | -45.81% | 12.31% | 23.69% | Upgrade
|
| EBITDA | -143.06 | -32.53 | -10.94 | 9.06 | 45.01 | Upgrade
|
| EBITDA Margin | -66.20% | -16.36% | -5.68% | 3.56% | 16.75% | Upgrade
|
| D&A For EBITDA | 8.11 | 8.13 | 3.01 | 2.73 | 2.84 | Upgrade
|
| EBIT | -151.17 | -40.66 | -13.95 | 6.33 | 42.17 | Upgrade
|
| EBIT Margin | -69.95% | -20.46% | -7.24% | 2.49% | 15.69% | Upgrade
|
| Effective Tax Rate | - | - | 60.42% | 44.47% | 21.75% | Upgrade
|
| Revenue as Reported | 216.11 | 198.77 | 192.64 | 254.38 | 268.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.